Pharsight

Lexiscan patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE47351 ASTELLAS 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
Jun, 2019

(4 years ago)

US8106183 ASTELLAS Process for preparing an A2A-adenosine receptor agonist and its polymorphs
Feb, 2027

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8536150 ASTELLAS Methods of myocardial perfusion imaging
Jun, 2019

(4 years ago)

US8470801 ASTELLAS Myocardial perfusion imaging methods and compositions
Jun, 2019

(4 years ago)

US8106029 ASTELLAS Use of A2A adenosine receptor agonists
Jun, 2019

(4 years ago)

US7655637 ASTELLAS N-pyrazole A2A receptor agonists
Jun, 2019

(4 years ago)

US7683037 ASTELLAS Myocardial perfusion imaging method
Jun, 2019

(4 years ago)

US7655636 ASTELLAS Use of A2A adenosine receptor agonists
Jun, 2019

(4 years ago)

US7582617 ASTELLAS Myocardial perfusion imaging method
Jun, 2019

(4 years ago)

US9289446 ASTELLAS Myocardial perfusion imaging methods and compositions
Jun, 2019

(4 years ago)

US7144872 ASTELLAS N-pyrazole A2A receptor agonists
Jun, 2019

(4 years ago)

US6642210 ASTELLAS 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
Jun, 2019

(4 years ago)

US9045519 ASTELLAS N-pyrazole A2A receptor agonists
Jun, 2019

(4 years ago)

US8183226 ASTELLAS Myocardial perfusion imaging method
Jun, 2019

(4 years ago)

US7183264 ASTELLAS N-pyrazole A2A receptor agonists
Jun, 2019

(4 years ago)

US8133879 ASTELLAS Myocardial perfusion imaging methods and compositions
Jun, 2019

(4 years ago)

US6403567 ASTELLAS N-pyrazole A2A adenosine receptor agonists
Apr, 2022

(2 years ago)

US9085601 ASTELLAS Process for preparing an A2A-adenosine receptor agonist and its polymorphs
Feb, 2027

(2 years from now)

USRE47301 ASTELLAS Process for preparing an A2A-adenosine receptor agonist and its polymorphs
Feb, 2027

(2 years from now)

Lexiscan is owned by Astellas.

Lexiscan contains Regadenoson.

Lexiscan has a total of 19 drug patents out of which 16 drug patents have expired.

Expired drug patents of Lexiscan are:

  • US8536150
  • US8470801
  • US8106029
  • US7655637
  • US7683037
  • US7655636
  • US7582617
  • US9289446
  • US7144872
  • US6642210
  • US9045519
  • US8183226
  • US7183264
  • US8133879
  • US6403567
  • USRE47351

Lexiscan was authorised for market use on 10 April, 2008.

Lexiscan is available in solution;intravenous dosage forms.

Lexiscan can be used as method for stimulating coronary vasodilation for purposes of imaging the heart, method of producing coronary vasodilation without peripheral vasodilation, a method of myocardial perfusion imaging and increasing coronary blood flow, method of myocardial imaging.

Drug patent challenges can be filed against Lexiscan from 10 April, 2012.

The generics of Lexiscan are possible to be released after 02 February, 2027.

Drug Exclusivity Drug Exclusivity Expiration
M(M-194) Jan 17, 2020
New Chemical Entity Exclusivity(NCE) Apr 10, 2013

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using REGADENOSON ingredient

NCE-1 date: 10 April, 2012

Market Authorisation Date: 10 April, 2008

Treatment: Method of myocardial imaging; Method for stimulating coronary vasodilation for purposes of imaging the heart; A method of myocardial perfusion imaging and increasing coronary blood flow; Method of pro...

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of LEXISCAN before it's drug patent expiration?
More Information on Dosage

LEXISCAN family patents

Family Patents